Atossa Therapeutics, Inc. (ATOS)
NASDAQ: ATOS · Real-Time Price · USD
0.7380
+0.0746 (11.25%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Atossa Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
95.33M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ATOS News
- 1 day ago - Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen Portfolio - GlobeNewsWire
- 13 days ago - Nona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast Cancer - PRNewsWire
- 4 weeks ago - Atossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Atossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 weeks ago - Atossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 6 weeks ago - Atossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional Indications - GlobeNewsWire
- 2 months ago - Atossa Therapeutics Congratulates Board Director Dr. Tessa Cigler and Weill Cornell Medicine on CDC Grant to Enhance Breast Cancer Care - GlobeNewsWire
- 2 months ago - Atossa Therapeutics Responds to PTAB Ruling on U.S. Patent No. 11,572,334 and Announces the Issuance of U.S. Patent No. - GlobeNewsWire